Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bridgebio Services Inc. is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is being reviewed by 1 distinct examiner in 1 distinct art unit, reflecting a focused prosecution strategy for the company's pharmaceutical inventions. This concentration indicates that the company's intellectual property is being evaluated within a single specialized group at the USPTO.
The busiest examiner for the portfolio is MONTGOMERY, ANN Y, who is responsible for 1 busiest examiner pending action. This action represents the total volume of 1 pending office action for the company. With only 1 distinct examiner and 1 distinct art unit involved, the company's current patent activity is concentrated in a specialized area. For practitioners, this means the examiner's interpretation of the prior art will be the factor in the success of the current prosecution efforts within that specific art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTGOMERY, ANN Y | 1 | 69.1% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | MONTGOMERY, ANN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | MONTGOMERY, ANN Y | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | MONTGOMERY, ANN Y | 1678 | §101§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBridgebio Services Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ann Y Montgomery has the most, with 1 of Bridgebio Services Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
